BHSTNasdaqPharmaceutical PreparationsFiscal year ends December 31

BIOHARVEST SCIENCES INC.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 31, 2026

$1.80−0.05 (-2.70%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

BIOHARVEST SCIENCES INC. income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Revenue	35	25	13
Cost of Revenue	14	11	7.04
Gross Profit	20	14	5.63
Research & Development	5.31	4.80	3.37
Operating Expenses	26	21	16
Operating Income	-5.58	-6.99	-9.97
Pretax Income	-11	-13	-13
Income Tax Expense	-0.08	-0.01	0
Net Income incl. Noncontrolling Interests	-11	-13	-13
Net Income	-11	-13	-13
EPS (Basic)(per share)	-0.60	-0.80	-0.93
EBITDA	-3.95	-5.74	-9.13

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: 59.3%
Operating margin: -16.2%
Net margin: -32.3%
Return on equity, FY2025: -83.2%

Financial strength

Current ratio: 3.97
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 299.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –